P/E ratio for Dynavax Technologies (DVAX)
P/E ratio as of May 2023 (TTM): 6.02
According to Dynavax Technologies 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 6.02151. At the end of 2021 the company had a P/E ratio of 23.1.
P/E ratio history for Dynavax Technologies from 2004 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 23.1 | -504.3% |
| 2020 | -5.71 | 120.43% |
| 2019 | -2.59 | -27.87% |
| 2018 | -3.59 | -64.69% |
| 2017 | -10.2 | 648.72% |
| 2016 | -1.36 | -81.52% |
| 2015 | -7.34 | 45.91% |
| 2014 | -5.03 | |
| 2012 | -6.95 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 7.26 | 20.55% | 🇺🇸 USA |
 Amgen AMGN | 14.6 | 143.25% | 🇺🇸 USA |
 Biogen BIIB | 13.8 | 129.41% | 🇺🇸 USA |
 Gilead Sciences GILD | 17.3 | 187.05% | 🇺🇸 USA |
 Merck MRK | 19.4 | 221.91% | 🇺🇸 USA |
 AstraZeneca AZN | 47.9 | 694.95% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 4.26 | -29.21% | 🇬🇧 UK |
 Agenus
AGEN | 6.90 | 14.67% | 🇺🇸 USA |
 Teva Pharmaceutical Industries TEVA | -3.51 | -158.36% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.